Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
82.500,38
-4,24%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xeris Biopharma Holdings Inc (XERS) Xeris Biopharma Holdings Inc (XERS) Notizie

Xeris Biopharma Holdings Inc

XERS
4,25
0,12 (2,91%)
08 Mar 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/3/202522:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/3/202522:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202513:21EDGAR2Form 8-K - Current report
27/2/202513:00BWXeris Biopharma to Report Fourth Quarter and Full-Year 2024..
24/2/202514:09EDGAR2Form 8-K - Current report
24/2/202514:00BWXeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
05/2/202514:00BWXeris to Participate in Upcoming Investor Conferences
04/2/202501:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/2/202501:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/1/202515:00PRNUSThe American Diabetes Association and Xeris Pharmaceuticals..
10/1/202513:17EDGAR2Form 8-K - Current report
10/1/202513:00BWXeris Expects to Exceed Full-Year 2024 Financial Guidance
07/1/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/1/202522:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202522:15BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
26/11/202413:00BWXeris to Participate in Piper Sandler 36th Annual Healthcare..
08/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202413:13EDGAR2Form 8-K - Current report
08/11/202413:00BWXeris Biopharma Reports Third Quarter 2024 Financial Results
31/10/202413:00BWXeris Biopharma to Report Third Quarter 2024 Financial..
04/10/202422:05BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
22/8/202413:00BWXeris to Participate in Upcoming Investor Conferences
09/8/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202422:27EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/8/202413:15EDGAR2Form 8-K - Current report
08/8/202413:00BWXeris Biopharma Reports Second Quarter 2024 Financial..
02/8/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202423:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/8/202422:14EDGAR2Form 8-K - Current report
25/7/202413:00BWXeris Biopharma to Report Second Quarter 2024 Financial..
08/7/202413:14EDGAR2Form 8-K - Current report
08/7/202413:00BWXeris Biopharma Announces CEO Succession Plan
03/7/202419:05BWXeris Announces Inducement Grants Under NASDAQ Listing Rule..
05/6/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202422:15EDGAR2Form 8-K - Current report
03/6/202413:00BWXeris Presents New Post Hoc Analysis on Effects of..
30/5/202413:30BWXeris Biopharma Announces Positive Topline Phase 2 Clinical..
30/5/202413:00BWXeris to Participate in the Jefferies Global Healthcare..
09/5/202413:14EDGAR2Form 8-K - Current report
09/5/202413:00BWXeris Biopharma Reports First Quarter 2024 Financial Results..
06/5/202413:00BWXeris Enters Into an Exclusive Worldwide Collaboration and..
02/5/202413:00BWXeris Biopharma to Report First Quarter 2024 Financial..
03/4/202422:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
02/4/202413:00BWXeris Biopharma to Participate in the 23rd Annual Needham..
Apertura: 4,12 Min: 4,05 Max: 4,40
Chiusura: 4,13

La tua Cronologia

NASDAQ
XERS
Xeris Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci